Your SlideShare is downloading. ×
0
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Ερευνητικό Κέντρο Βιοϊατρικών Επιστημών "Αλέξανδρος Φλέμινγκ"

1,831

Published on

Δρ. Στρουμπούλη Ιωάννη, Αναπληρωτή Καθηγητή Έρευνας, Ινστιτούτο Μοριακής Ογκολογίας που παρουσιάστηκε στην εκδήλωση "Life Sciences Business Day", Electra Palace Hotel, Αθήνα, 16/10/2008 (Hellenic Bio …

Δρ. Στρουμπούλη Ιωάννη, Αναπληρωτή Καθηγητή Έρευνας, Ινστιτούτο Μοριακής Ογκολογίας που παρουσιάστηκε στην εκδήλωση "Life Sciences Business Day", Electra Palace Hotel, Αθήνα, 16/10/2008 (Hellenic Bio Cluster).

Published in: Education, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,831
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Biomedical Sciences Research Center “Alexander Fleming” Fleming” Greek Life Sciences Business Day, October 16 2008 Day, John Strouboulis, PhD Strouboulis,
  • 2. Who we are • Fleming Started its activities in 1998 as a Private Legal Entity • Supervised by the GSRT, Greek Ministry of Development
  • 3. Who we are • Four Research Institutes currently active • Immunology • Molecular Biology and Genetics • Molecular Oncology • Cell and Developmental Biology • (Microbiology and Virology) • Scientific personnel-our most important asset • 14 group leaders, more than 130 research staff (staff scientists, grad students, technicians, postdocs) • Young scientists, international experience, high caliber
  • 4. What we do • Institute of Immunology – Pathogenesis of inflammatory pathways (Kollias, Aidinis, Graf, Douni, Mosialos) – Posttranscriptional gene regulation in inflammation and cancer (Kontoyiannis) – Angiogenesis (Kostourou) • Institute of Molecular Biology and Genetics – Epigenetic mechanisms of gene regulation in physiology and cancer (Talianidis, Agalioti) – Neuronal stem cells (Remboutsika) – Neurobiology of learning and memory, neurodegeneration (Skoulakis) • Institute of Molecular Oncology – Signaling pathways in cancer (Panayotou) – Hematopoiesis and leukemia (Strouboulis) – microRNA bioinformatics (Hatzigeorgiou)
  • 5. How we do it: Technology Platforms Functional Functional Genetics Genomics Transgenesis Bioinformatics Mutagenesis Phenomics Animal Biochemistry models Imaging Molecular Proteomics Cellular Genomics Genetics
  • 6. Our Achievements • Achievements/Awards – National and International Awards for researchers (Bodosakis’ Foundation, EMBO, Leukemia and Lymphoma Society) – High Impact Scientific Publications – Awards of competitive national and international grants – Coordinator of an EU FP6 ‘Network of Excellence’ NoE in Functional Genomics, €11m, 2005-2009 – Coordinator of an FP7 Marie Curie Initial Training Network on Gene Regulation, €2.3m, 2008-2012 – 2002 and 2005: Centre of Excellence by international review committee under the auspices of the Ministry of Development
  • 7. Our Funding 6 projected 5 4 Funding 3 (million euros) 2 1 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Year
  • 8. Our Funding Other income 1,20% Services Services Govt. subsidy Company contracts 1,50% Govt. subsidy 6,50% 15% 2,50% 17,50% Company contracts 9% EU grants 28,30% 31% 37% 50% EU grants National grants National grants 2005 2008 Total: € 4.4m Total: € 5.4m* * projected
  • 9. Our Products and Services – Proprietary animal models for human disease, e.g. inflammatory, neurodegerenative diseases. Preclinical drug testing and validation – Cutting edge technical services and facilities built on needs, capacities and expertise of Fleming’s researchers. Available to external users as services – Valorization • Building intellectual property portfolios • Spin off companies
  • 10. Animal models of human disease: inflammatory disorders Joint Small intestine Normal Disease Transgenic mice pathogenesis or Knockout mice TNF pathway Inflammation Rheumatoid Arthritis Crohn’s disease • Understanding pathogenesis • Preclinical drug evaluation • New therapeutic and diagnostic target identification George Kollias group (RA, Crohn’s, EAE etc.)
  • 11. Animal models of inflammatory disease: preclinical evaluation contracts Contracts with: 250 • Centocor • Isis Pharma 200 • BASF • Amgen • Merck 150 Revenue • Medidom (x1000 €) • Abbott 100 • Novo Nordisk • Celltech 50 • Millenium Pharma • Domantis • Peptech 0 2000 2001 2002 2003 2004 2005 2006 • Ablynx • Direvo Year • Debiopharm • Abgenix Fleming’s first spin-out company • Chemocentryx
  • 12. Company Profile Founded: last quarter of 2006 as a spin off company of BSRC Al. Fleming. Services: Pre-clinical drug evaluation models and services using transgenic mice Humanized transgenic models of autoimmune and inflammatory conditions (arthritis, cachexia, sepsis, multiple organ failure, inflammatory bowel disease) Induced models (CIA, EAE, sepsis etc) Gene expression profiling Customized protocols Histopathology Mouse Models: proprietary, world recognized for human disease, FDA recommended. Facilities: independent laboratories/offices R&D: Active generates new and novel humanized mouse models. Participates in FP6 and FP7 European grants Staff: Six well trained and experienced scientific personnel Clients: Big Pharma, Biotechnology companies (Europe, USA, Australia)
  • 13. Animal models of human disease: Alzheimers in Drosophila 30 25 20 Revenue (x1000 €) 15 10 5 normal 0 2004 2005 2006 EnVivo Pharma Fly school: Μemory and learning, lesions enhancing compounds? 30 day old aged fly Makis Skoulakis group
  • 14. Fleming Service Units and Facilities • Protein Chemistry Lab, ISO Certified • Animal House, ISO Certified • Transgenic Facility, ISO Certified • Genotyping Facility • Expression Profiling Facility and BioIT Unit • Flow Cytometry Facility • Innovation and Enterprise Unit
  • 15. Protein Chemistry Lab Cutting edge services in biomolecular and protein interaction characterization Protein identification by mass spectrometry Mapping of protein post-translational modifications Protein expression, purification and characterization Protein fractionation by various electrophoretic methods 2D protein electrophoresis BIACORE Peptide fractionation by high pressure chromatography Analysis of biomolecular interactions by biosensors Analyte identification in clinical samples Protein and nucleic acid quantitative analysis Mass spectrometry FPLC Head: Dr. George Panayotou EN ISO 9001:2000 Certification HPLC
  • 16. Protein Chemistry Lab National Cancer Institute McGill University 100 University College London 90 Wyeth Hellas 80 Schering-Plough 70 Aristotelian University, Thessaloniki Revenue Ludwig Institute for Cancer Research (x1000 €) 60 Hellenic Pasteur Institute 50 BioCryst Inc. 40 Athens University Medical School Kimmel Cancer Center 30 University of Ioannia 20 National Metsovion Technical University 10 Agios Savvas Hospital 0 University of Thessaly 2002 2003 2004 2005 2006 2007 2008 Dimokritos Research Center Erasmus University Patras University Head: Dr. George Panayotou
  • 17. Animal House • Biggest facility in Greece – 600m 2, capacity for 18,000 mice – 8 caretakers, 2 technicians, 2 senior scientists – EN ISO 9001.2000 certification • Services – Breeding, hosting and supply of mouse strains, wild type and transgenic – Handling of mice, surgical procedures, sample taking – γ irradiation for bone marrow transplantation – Histology lab – Internal and external users Head: Dr. Marie Kamber
  • 18. Laboratory Animal Science Course
  • 19. Genotyping Facility Clinical diagnostics • Mutation screening • Customized mutation screening assays • Pharmacogenetics • CpG methylation status quantification • Microbial / viral detection and resistance assessment Head: Dr. Eleni Douni Pyrosequencing
  • 20. Expression Profiling Facility and BioIT Unit • Affymetrix platform for RNA expression analysis, e.g. clinical samples • Illuminex platform for multiplex analysis of several markers • Bioinformatic analysis and support, data mining Head: Dr. Vasilis Aidinis
  • 21. The future • Participation in European Research Infrastructures, e.g. Infrafrontier • Implementation of the entire drug discovery and development process • Business development through IP portfolios, spin off companies • Biotechnopolis
  • 22. Infrafrontier The European Infrastructure for phenotyping, archiving and dissemination of disease (mouse) models • Germany: GSF; HZI • UK: MRC/MGU, Welcome Trust Sanger; EBI • France: ICS, CDTA/CDTA • Italy: CNR; Government • Sweden: Karolinska • Spain: Univ. Barcelona; Madrid • Portugal: Gulbenkian Institute • Greece: Fleming Center • Finland: Biocenter Oulu
  • 23. The Biomedical and Life Sciences Infrastructure Landscape
  • 24. Drug Discovery Process Preclinical In vivo Tests Target Clinical Trials Pharmacology Identification ADMET profiles Lead Optimization Signal 2: ATP [%] Genomics Frequency Chemoinformatics > 300% Hits Proteomics UnspezifischCompound Häufigkeit oder toxisch Control Target < 60 % Validation SignalLigand 1: [%] Functional Data Mining Assay Development Genomics – Virtual Screening Animal models Lead Identification
  • 25. The future • Participation in European Research Infrastructures, e.g. Infrafrontier • Implementation of the entire drug discovery and development process • Business development through IP portfolios, spin-out companies • Biotechnopolis
  • 26. Innovation & Enterprise Unit • Formerly Technology Transfer Office • Established in 2005 with GSRT Grant – Now funded directly via Fleming • Responsible for: – Management of Fleming IP – Business Development Activities for Fleming IP – Negotiation of R&D contracts • Material Transfer Agreements • Contract Research • Collaborative Research • Service Agreements etc • More than 300 agreements managed in the last 3 years
  • 27. Innovation & Enterprise Unit Achievements • Patent portfolio around 2 technologies – License for one patent under negotiation – Other patent applications under consideration • Supported establishment of BioMedCode, Fleming’s first spin-out company • Established working relationship with several big pharmas via major Biotech conference – Negotiating collaborative deals now! – Maintain contact with others for the future…
  • 28. THE ALEXANDER FLEMING BIOTECHNOPOLIS Research Institutes Mouse clinic Technology park • Second building for Fleming’s Research Institutes, Facilities and European Research Infrastructures • New research centers with complementary research activities • Biobusiness park, incubator space, tech transfer services • Science in Society Cultural Center, housing the Alexander Fleming Museum, Science Sculpture Park, Conference Center facilities

×